Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Galeterone |
Synonyms | |
Therapy Description |
Galeterone functions both as an inhibitor of CYP17A1 and anti-androgen, as it binds the androgen receptor, acting as an competitive antagonist and also preventing Ar protein binding to chromatin and enhancing degradation of mutant Ar protein (PMID: 24874833, PMID: 31653008). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Galeterone | TOK-001|VN-124 | Hormone - Anti-androgens 54 | Galeterone functions both as an inhibitor of CYP17A1 and anti-androgen, as it binds the androgen receptor, acting as an competitive antagonist and also preventing Ar protein binding to chromatin and enhancing degradation of mutant Ar protein (PMID: 24874833, PMID: 31653008). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04098081 | Phase II | Galeterone + Gemcitabine Galeterone | 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT02438007 | Phase III | Galeterone Enzalutamide | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01709734 | Phase II | Galeterone | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer | Terminated | USA | CAN | 0 |